Efficacy and Safety of Moxifloxacin vs Clarithromycin for Community-Acquired Pneumonia

Infections in Medicine

Volumn 16, Issue 11, 1999, Pages 748-763

  Fogarty, Charles ^a   Grossman, Colby ^b   Williams, James ^c   Haverstock, Daniel ^c   Church, Deborah ^c  

^a Spartanburg Pharmaceutical Research ^*  (United States)

^b Summerville Medical Center   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Chlamydia pneumoniae; Clarithromycin; Haemophilus influenzae; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, community acquired (CAP); Streptococcus pneumoniae

Indexed keywords

CLARITHROMYCIN; MOXIFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME;

EID: 0032723032     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts - United States. MMWR. 1997;46:556.
2. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA. 1995;275:189-193.
3. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
4. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management (Infectious Diseases Society of America). Clin Infect Dis. 1998;26:811-38.
5. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996;101:508-515.
6. Doern GV, Brueggemann AB, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
7. Doern GV, Brueggeman AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:2884-2886.
8. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase positive strains resistant to amoxicillin-clavulanate: results of a national multicenter study. Antimicrob Agents Chemother. 1997;41:292-297.
9. Felmingham D, Gruneberg RN, and the Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother. 1996; 38(suppl A):1-57.
10. Gruneberg RN, Felmingham D, and the Alexander Project Group. Results of the Alexander Project A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis. 1996;25:169-181.
11. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1995-1997 respiratory season. Diagn Microbiol Infect Dis. 1997;29:249-257.
12. Thornsberry C, Ogilvie P, Holley HP Jr. The susceptibility of penicillin-susceptible and -resistant S. pneumoniae to 26 antimicrobial agents. In: Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America; September 13-16, 1997; San Francisco. Abstract 900.
13. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 1997;41:1594-1597.
14. Roblin PM, Hammerschlag M. Activity of BAY 12-8039, a new 8-methoxyquinolone, against Chlamydia pneumoniae in vitro. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans. Abstract F11.
15. Stass HH, Kubitza D. Crossover study to assess absolute bioavailability (AB) and absorption characteristics (AC) of moxifloxacin in man. In: Program and abstracts of the 8th International Congress on Infectious Diseases; May 15-18, 1998; Boston. Abstract 59.005.
16. Stass HH, Dalhoff A, Kubitza D, Ahr G. Bay 12-8039, a new 8-methoxyquinolone: first pharmacokinetic results in healthy male volunteers. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans. Abstract F24.
17. Stass H, Dalhoff A, Kubitza D, Schühly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new-8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42:2060-2065.
18. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard. M7-A3. 3rd ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
19. Performance Standards for Antimicrobial Disk Susceptibility Tests Approved Standard. M2-A5. 5th ed. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
20. Verkooyen RP, Willemse D, Hiep-van Casteren SC, et al. Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections. J Clin Microbiol. 1998;36:2301-2307.
21. Chow AW, Hall CB, Klein JO, et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. (Infectious Diseases Society of America and the Food and Drug Administration). Clin Infect Dis. 1992;15(suppl 1):S62-S88.
22. Patel T, Pearl J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Respir Med. In press.
23. Cassell G, Drnec J, Waites KB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother. 1991;27(suppl A): 47-59.
24. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother. 1991;27(suppl A):117-124.
25. Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia: a multi-center, double-blind, randomized study comparing clarithromycin with erythromycin. Chest. 1993;103:697-701.
26. Macfarlane JI. Treatment of lower respiratory tract infections. Lancet. 1987;2:1446-1449.
27. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis and treatment. Clin Infect Dis. 1995;21:5244-5252.
28. Verkooyen RP, Hazenberg MA, Van Haaren GH, et al. Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor. J Clin Microbiol. 1992;30:1287-1290.
29. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA. 1995;274: 134-141.
30. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995; 333:474-480.